Recall issued for several own label glycerine and blackcurrant cough syrups

Recall issued for several own label glycerine and blackcurrant cough syrups

June 20 2018 A Class 2 Drug Recall has been issued for 15 batches of own-brand children’s...

Bath emollients have ‘no benefit beyond standard eczema care for children’

Bath emollients have ‘no benefit beyond standard eczema care for children’

May 9 2018 A study has found no evidence of clinical benefit from including bath emollients in...

Cochrane: honey rated better for children’s cough than some OTC preps or placebo

Cochrane: honey rated better for children’s cough than some OTC preps or placebo

April 16 2018 Honey appears likely to help children’s cough more than diphenhydramine, a...

OTC Viagra Connect availability to widen following launch via Boots

OTC Viagra Connect availability to widen following launch via Boots

April 11 2018 Viagra Connect should be available from most pharmacies at the end of this week,...

MHRA issues warning over flammability of headlice treatments

MHRA issues warning over flammability of headlice treatments

March 9 2018 Pharmacists have been asked to tell customers about the risk of fire when discussing...

  • Recall issued for several own label glycerine and blackcurrant cough syrups

    Recall issued for several own label glycerine and blackcurrant cough syrups

    Wednesday, 20 June 2018 18:29
  • Bath emollients have ‘no benefit beyond standard eczema care for children’

    Bath emollients have ‘no benefit beyond standard eczema care for children’

    Wednesday, 09 May 2018 15:28
  • Cochrane: honey rated better for children’s cough than some OTC preps or placebo

    Cochrane: honey rated better for children’s cough than some OTC preps or placebo

    Monday, 16 April 2018 09:13
  • OTC Viagra Connect availability to widen following launch via Boots

    OTC Viagra Connect availability to widen following launch via Boots

    Wednesday, 11 April 2018 12:52
  • MHRA issues warning over flammability of headlice treatments

    MHRA issues warning over flammability of headlice treatments

    Friday, 09 March 2018 16:15

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageNovember 30 2017

A drug alert has been issued for a batch of Calcichew-D3 500mg/400 IU Caplets manufactured by Takeda, as sampling found traces of a non-approved excipient. The affected batch has batch number 11372123 and expiry date May 2019.

The MHRA alert says that “a Patchouli-like oil” had “inadvertently been added to the lemon flavouring used in the manufacture of the tablets. Takeda has no reason to believe that the non-approved substance poses a significant risk to public health.”

The alert makes no reference to removing the batch from stock. For stock information, pharmacists should contact Alloga UK on 01773 510123, and for medical information, contact Takeda UK Ltd on 01628 537900 or email This email address is being protected from spambots. You need JavaScript enabled to view it.

Link:
MHRA alert        

OTC News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 19 2018 A practice-based audit will seek to explore community pharmacy’s contribution in supporting girls and women of childbearing potential who need to take valproate medicines. Launched by...